Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAFENO: Rosuvastatin + Fenofibrate vs Rosuvastatin in CAD
NCT02232360Phase 4Unknown
- Sponsor
- Gachon University Gil Medical Center
- Start
- Jan 2014
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of fenofibrate in coronary artery disease (CAD) and dyslipidemia (2 arms), sponsored by Gachon University Gil Medical Center. Primary endpoint: Percent and Absolute changes of Necrotic Core volume in non-culprit intermediate lesions at 12 months. Status: unknown.
02
Drugs
fenofibrate
03
Conditions
coronary artery disease (CAD)dyslipidemia
Beyond the preview
Go deeper on NCT02232360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02232360.